Collaboration to accelerate the development and access of oncology medicines for cancer patients in China
Clinical trial programs combining two of Sanofi's prioritized oncology assets with sintilimab, the leading checkpoint inhibitor in China, to address some of the most prevalent solid tumors in China
Sanofi to make an initial equity investment of
